Core Insights - Gilead Sciences, Inc. (NASDAQ:GILD) is recognized as a leading immunotherapy stock by hedge funds, reporting strong fiscal Q4 and full year 2025 results, driven by the growth of Biktarvy, Descovy, and the launch of Yeztugo, the first twice-yearly HIV prevention therapy in the country [1] Financial Performance - Total fiscal Q4 revenues increased by 5% to $7.9 billion compared to the previous year, primarily due to higher sales of HIV and Liver Disease products, although this was partially offset by lower sales of Veklury® [2] Analyst Ratings - Following the earnings release, several analysts updated their ratings for Gilead. Needham raised the price target to $170 from $140 while maintaining a Buy rating, and Scotiabank increased its target to $177 from $140, keeping an Outperform rating [3] - BofA also raised its price target to $162 from $154, maintaining a Buy rating, and expressed confidence in the company's growth for 2026 based on strong fiscal Q4 performance [4] Company Overview - Gilead Sciences, Inc. is a biotech company focused on developing medicines for serious diseases, including cancer, HIV, viral hepatitis, and COVID-19, with a portfolio that addresses unmet medical needs [5]